Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataZolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlationsEffect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjectsUse of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases.Summary of information on human CYP enzymes: human P450 metabolism data.A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction predictionDrug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy AdultsEffects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.Metabolism-based drug interactions involving oral azole antifungals in humans.Clinically significant pharmacokinetic drug interactions with benzodiazepines.Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy.The human CYP3A subfamily: practical considerations.Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteersEffect of itraconazole on the pharmacokinetics of diclofenac in beagle dogs.Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.Clinical relevance of P-glycoprotein in drug therapy.CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsInfluence of ketoconazole on azimilide pharmacokinetics in healthy subjects.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjectsEffect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolitesEffect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.Transporter-mediated drug interactions: clinical implications and in vitro assessment.Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesComputing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions.Computing with evidence Part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment.
P2860
Q27009128-5B68C061-FC09-425E-B711-955DCCDDC76DQ28343408-E096C620-2ED4-468B-9CB2-B6BFF3FACE23Q28367515-05D1489F-6989-4B13-BFEF-E8A018D94583Q31900846-DD0301B3-9BE3-4196-85B2-C04CF4E23283Q32103802-07C8705A-54E2-4E47-8423-D18DE9EDDE49Q33383326-F32A44FB-EBBD-4ADD-A1E1-6391C13D4E6DQ33571585-28AFE0F6-5ADA-4601-B908-504B33A2BA6BQ33668215-88829541-0183-46FD-812D-E3EAA2D3EE29Q33719828-38A4C1C4-52E4-4A4B-8C7A-40C53F094D57Q33785867-F42CFC8E-303C-4246-BF4F-6CD84C4074BFQ33887999-EA9B3DCA-D107-436F-9551-1B85FE765D97Q33998081-8942A656-7F96-4A53-BFE7-B5BDEF8D0553Q34119161-872C0F81-F2A4-4534-9DE6-3F3BAF5BA622Q34347427-03BB2062-5932-428B-A1FB-BBF8FDCA92A7Q34409954-216C8E5F-4F8D-4B17-969C-8E44609BCFD2Q34429206-73449910-C99E-42AB-A144-49AC2171F624Q34476096-76608B98-EC0D-4F7C-B97F-237CB9C33421Q34514087-6F74D3A3-5504-4298-ABBB-F36F91042DB2Q34548528-886B6038-382D-426F-9016-E1830187CC32Q34563883-B8DCFB82-DBFA-4349-8449-FAC83C6B6D99Q35129048-1D6A9985-96F4-42DD-B5E6-35253BF1761DQ35557449-7864AFBF-3B6B-4A01-B551-940C7CE4AA49Q35608207-8F18A2C0-FF2B-49EA-8EDB-237416E3F6E3Q35620664-27CB5182-9F24-421D-97B5-09EE179EEAFAQ35718619-18C907C3-C860-4508-86E4-A806C746C80DQ35826014-00AD764E-C28E-4A6E-A48C-2B09E32598FCQ35826541-0B29115D-C0BB-4B66-848E-79774EA34007Q35827146-ADB98C7A-EBFF-41E3-AF05-F2484100F65EQ36018865-0E59E547-203B-4893-B9C5-BA26D32D5C17Q36024937-51B3DE25-2538-4EFD-87A5-4BA6ABB1480BQ36055339-7CCE374C-635C-4333-9875-526954369572Q36072448-843C6EB8-C44D-47DA-BC8A-5CD986157943Q36105348-E0D4A053-FC52-41AB-9A03-0C743A1B3EA7Q36558235-9AC69608-54BA-433C-ADEE-11EB2825BBEAQ36593846-87470D9C-8EF9-480E-8D1D-05B72032EBCFQ36725222-EAE46B7A-CAC2-4D79-97BA-0506F9B92132Q36803396-9DF620CA-390E-45F0-9CD5-90A00BFE86E9Q37184796-9D81FCF7-79C1-4B81-B23E-F4364E0EE638Q37440022-CECC395F-F7FC-49D6-9630-DBCB46BDE9D8Q37440590-A14FB7DA-9761-4B52-B41F-0711ABCB8BA5
P2860
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@en
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@nl
type
label
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@en
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@nl
prefLabel
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@en
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@nl
P2093
P356
P1476
Midazolam should be avoided in ...... ketoconazole or itraconazole.
@en
P2093
Backman JT
Neuvonen PJ
Olkkola KT
P304
P356
10.1038/CLPT.1994.60
P407
P577
1994-05-01T00:00:00Z